SAN HQ developed by ArcticZymes has quickly found its place as a valuable tool in manufacture of gene-delivery vehicles (viral vectors) applicable in gene therapy. In cooperation with the Cell and Gene Therapy Catapult, a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK, ArcticZymes presented a scientific poster at the “Cell Therapy Manufacturing & Gene Therapy Congress 2019” in Amsterdam December 3rd–6th. The poster describes why SAN HQ is such an effective tool in the removal of DNA impurities from viral vectors in the manufacturing process. In brief, DNA impurities are more accessible as salt concentration is increased, this coincides with SAN HQ’s optimal performance characteristics. The result is an increase in the efficiency of DNA removal and a decrease in the time to manufacture.
The Cell and Gene Therapy Catapult is supported by Innovate UK to assist cell and gene therapy organizations across the world to translate early stage research into commercially viable solutions. ArcticZymes is proud to work with such a renowned leader in the Gene therapy field and to demonstrate the unique properties ArcticZymes nuclease portfolio brings to the Gene therapy field.
ArcticZymes AS is pleased to announce the launch of dsDNase Glycerol-free Triton FREE. This launch is a continuing step towards maintaining a completely EU REACH compliant product portfolio after Triton X-100 becomes subject to authorisation in January 2021 and facilitate a smooth transition for our existing dsDNase customers.
dsDNase Glycerol-free Triton FREE is available for shipping. You can request a quote by contacting your local Business Development Manager or using this form
December 10, 2019
ArcticZymes is pleased to announce a new and novel member of the Salt Active Nuclease (SAN) portfolio; M-SAN High Quality. The new SAN enzyme builds on the highly demanded SAN High Quality nuclease serving the bio-manufacturing market segment. While SAN HQ is designed to work in the high salt concentration range, M-SAN HQ has been developed to offer the optimal solution for removal of nucleic acids at physiological salt conditions. High activity at physiological salt conditions is very relevant in many bioprocessing and biomanufacturing workﬂows in which currently available nucleases are ineffective. Thus M-SAN HQ can help avoid unnecessary steps in the workflows and by doing so increase efficiencies and the utility of the enzyme.
“We are excited to expand our product portfolio within the bio-manufacturing markets where our unique technologies can have a major impact. The new edition to our SAN products can greatly help both new and current customers” says Dr. Jethro Holter, Interim CEO, Biotec Pharmacon.
ArcticZymes is currently developing an ELISA-kit for M-SAN which is expected to be launched within 2020. Prototypes of the kit will be made available for testing by key customers prior to launch. M-SAN will be available for shipping from January 2020. Request a quote today here or by contacting your local Business Development Manager.
To learn more about M-SAN, visit the technology page, or check out the brochure.
ArcticZymes AS is pleased to announce the launch of HL-dsDNase Glycerol-free Triton FREE. This launch is a continuing step towards maintaining a completely EU REACH compliant product portfolio after Triton X-100 becomes subject to authorisation in January 2021. The convenient glycerol-free formulation is suitable for lyophilization and automated processes. The new formulation offers the same advantages as HL-dsDNase, such as strong preference for double stranded DNA and heat inactivation at low temperatures.
HL-dsDNase Glycerol-free Triton FREE is available for shipping. You can request a quote by contacting your local Business Development Manager or using this form.